Brought to you by 
Aveo gets VEGF receptor inhibitor from Kirin Brewery
06 Aug 2020
Executive Summary
Aveo Pharmaceuticals (genomics for cancer drug discovery) has licensed from Kirin Brewery exclusive worldwide rights (excluding Asia) to develop and commercialize KRN951, a Phase I oral VEGF receptor inhibitor.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Aveo gets VEGF receptor inhibitor from Kirin Brewery
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice